Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have a solid financial foundation as we prepare for multiple upcoming data readouts and regulatory milestones and as we continue investing in the expansion of our deep pipeline |
| So it's a very exciting advancement in the field |
| We're extremely proud of the progress we've made throughout 2023 and so far in 2024 |
| This private placement further strengthened our financial position with approximately $900 million on a pro forma basis |
| 2023 was a tremendously successful year for Crinetics on many fronts |
| Paltusotine continues to deliver impressive results in the two indications for which it is being developed, acromegaly and carcinoid syndrome |
| We are very excited about these results that demonstrate durable symptom and biochemical control through a convenient once-daily oral option for patients, who are currently burdened by depot injections |
| And I think -- but I've been around this endocrine systems since the earliest days of my career, and CRF is a very exciting molecule that has some wonderfully interesting biologies |
| From a safety point of view, Paltusotine continues to be well tolerated in this patient population consistent with what we've seen from our other clinical studies to-date |
| We are also very pleased to have already observed meaningful reductions in the two key symptoms of carcinoid syndrome, excess bowel movements and flushing episodes, even in the initial look at the data |
| We know that PATHFNDR-1 data is resonating well, creating excitement among the acromegaly and carcinoid syndrome prescribers and the patients |
| So super excited to see that |
| We're very appreciative of the continued support that we've received from new and existing shareholders, who share our long-term vision for building the premier endocrine company to help patients suffering from a wide range of different endocrine-related diseases |
| In September we reported clinical results in acromegaly that exceeded expectations |
| Paltusotine’s second target indication, carcinoid syndrome, is also showing promising results to-date |
| And I think you can look for a strong presence from -- us there in Boston this June |
| And maybe I'm tooting our horn a little bit, but I think the guys in the next labs down the hall here are some of the best in the world -- guys and gals, sorry, are some of the best in the world at making drugs like that |
| And 2024 is poised to be a transformative year for Crinetics |
| We ended 2023 on strong financial footing with $558.6 million in cash and investments |
| In terms of -- we've had a number of advisory boards with physicians and also market research with payors, and I will tell you that based on the PATHFNDR-1 data, the response has been very, very enthusiastic |
| And so, we're very excited to see how this plays out next month |
| Scott Struthers Actually, I think it's important to point out that, that's fairly unique amongst the SRLs, and we're very excited about it |
| This is a high-quality list of new and existing investors with a long-term view that understand and want to support the long-term growth and vision of our company |
| From a safety point of view, Paltusotine was well tolerated with no new safety findings, consistent with what we've seen in our previous studies |
| But like I said, in many of our programs, it's not about the efficacy, it's about finding the great drug that also has the great efficacy |
| For example, you may recall from our interim data report, we -- I was very excited to see not only are the numbers of excess bowel movements and flushing episodes reduced on Paltusotine, but also the urgency of those associated bowel movements and also the severity of those flushing episodes were also very meaningfully reduced |
| But we think we have a good handle on comparing to more recently done research, particularly in naive patients with acromegaly |
| Alan Krasner Yes, so I mean, I was pretty impressed with our interim data reported in December, I thought that was pretty winning stuff already |
| We will also continue to invest in our world-class discovery capabilities that are the roots of our long-term success |
| We are excited about this initial data and look forward to reviewing the full top-line results, which are anticipated in the first-half of this year |
| Statement |
|---|
| This excess ACTH causes overstimulation of the adrenal cortex, resulting in overproduction of androgens |
| It's a problem |
| These patients have impaired cortisol production, which causes high levels of ACTH |
| So in Cushing's disease with excess glucocorticoids or in CAH patients with excess glucocorticoids, you're adding too much adiposity, you're increasing blood pressure, you're damaging bone |
| And when things go wrong in that pathway, bad things happen |
| Those receptors then act on those cells and on the IGF receptors on those cells to cause the hypertrophy that results in the protrusion and other problems in the back of the eye |
| I know everybody wants to see it, but nobody worse than me |
| And the TSH receptor is the root problem |
| However, it is important to note that the absolute IGF-1 normalization rates in PATHFNDR-2 is expected to be lower than that observed in the PATHFNDR-1 population |
| Such forward-looking statements are not a guarantee of performance and the company's actual results could differ materially from those stated or implied such statements due to risks and uncertainties associated with the company's business |
| Our net loss for the quarter ended December 31, 2023 was $60.1 million, compared to a net loss of $45 million for the same period in 2022 |
| For the year ended December 31, 2023, the company's net loss was $214.5 million, compared to a net loss of $163.9 million for the same period in 2022 |
| So, we're going to the root of the problem |
| If it's very high, it's going to take more lowering to get to normal |
| Just wondering if you could give some context about how you think the opportunity for Paltusotine changes in acromegaly if you just have a maintenance label versus a maintenance and treatment label? And then seems like a lot of excitement 4894 and CAH in Cushing's has been a difficult indication and the dynamics are changing there |
Please consider a small donation if you think this website provides you with relevant information